Improving STING agonist-based cancer therapy by inhibiting the autophagy-related protein VPS34

Abstract

We have recently demonstrated that inhibiting VPS34 enhances T-cell-recruiting chemokines through the activation of the cGAS/STING pathway using the STING agonist ADU-S100. Combining VPS34 inhibitors with ADU-S100 increased cytokine release and improved tumor control in mouse models, suggesting a potential synergy between VPS34 inhibition and therapies based on STING agonists.

Keywords

• Autophagy
• CCL5
• CD8 T cells
• CXCL10
• immunotherapy
• melanoma